CompletedNot Applicable

Prospective Study of the Prognostic Value of New Markers in Adults With ALK-positive Large Anaplastic Lymphoma

France41 participantsStarted 2018-08-02

Plain-language summary

The study aims to evaluate the prognostic value on the complete metabolic response rate (MCR), the incidence of relapse / progression, the Progression Free Survival (PFS) and the Overall Survival (OS). * at diagnosis * after the first cycle of CHOEP (early evaluation) * at the end of treatment

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: Over 18 years old Diagnosed with Anaplastic large-cell lymphoma ALK+ Planned treatment : 6 cycles of CHOEP 21 Planned lumbar puncture at diagnosis or at the first cycle with intrathecal prophylaxis with methotrexate (15 mg) at the first cycle Planned interim positron emission tomograph (PET)-scan after 3 cycles of treatment and at the end of treatment according to the center standard of care Exclusion Criteria: Involvement of the central nervous system Intent of Autologous stem-cell transplant in first line

What they're measuring

Prognostic value of biological parameters on the complete metabolic response rate (MCR)

Timeframe: Day 0

Trial details

NCT IDNCT03603847

SponsorThe Lymphoma Academic Research Organisation

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2023-06-16

View on ClinicalTrials.gov More Anaplastic Large Cell Lymphoma, ALK-Positive trials